Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation

Sai Ravi Kiran Pingali, Michelle Mathiason, Steven Lovrich, Ronald Go

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

We report the emergence of chronic myelogenous leukemia (CML) in a patient with JAK2V617F-positive polycythemia vera after 15 years of phlebotomy. The polycythemia vera clinical and molecular findings were suppressed at the time of CML diagnosis, only to re-emerge after the leukemia was successfully treated with imatinib. We explored the potential association between myeloproliferative disorders and CML in the context of the current literature and found a higher-than-expected coincidence based on known epidemiologic data for each specific condition. We hypothesize that myeloproliferative disorder (JAK2V617F or molecular events that cause JAK2V617F) is a risk factor for CML (BCR-ABL translocation). Because of therapeutic implications, clinicians should be aware that the conditions co-occur more frequently than once thought.

Original languageEnglish (US)
Pages (from-to)E25-E29
JournalClinical Lymphoma and Myeloma
Volume9
Issue number5
DOIs
StatePublished - Oct 1 2009

Bibliographical note

Funding Information:
The authors thank Cathy Mikkelson Fischer, MA, for editing the manuscript. Ronald S. Go is supported by the Gundersen Lutheran Center for Cancer and Blood Disorders and the Gundersen Lutheran Medical Foundation.

Keywords

  • Erythrocytosis
  • Myelofibrosis
  • Phlebotomy
  • Polycythemia vera
  • Sleep apnea

Fingerprint

Dive into the research topics of 'Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation'. Together they form a unique fingerprint.

Cite this